Suturion has recently patented their innovation and the clinical study will begin shortly.
We have submitted the application and our hope and plan is to start with the first patients before end of the year, says Suturion’s CEO Paan Hermansson (left in the picture). Suturion was founded by surgeon Gabriel Börner (right in the picture).
A total of 38 patients with planned operations will be included in the clinical trial with Suturion’s sewing machine at Helsingborg’s hospital. These are mainly patients with cancer or inflammatory bowel disease, IBD. The study report is expected to be ready in June, and the product launch is planned towards the end of 2023.
According to the company, the technology makes suturing – which today is often performed by AT and ST doctors during training – faster, easier, and safer. In the long run, the technology should mean a cost saving for care, as the complications after inadequate abdominal wall closure should be greatly reduced.
– We raise the quality of the suture line, which means that the surgeon can delegate the task to a less experienced surgeon with a better conscience, says Paan Hermansson.